Literature DB >> 788738

Comparison of salmefamol and salbutamol in patients with chronic airways obstruction.

I A Campbell, C H Dash, G J McHardy, M V Shotter.   

Abstract

1 Inhaled salmefamol, in doses of 100 mug and 200 mug has been compared with inhaled salbutamol, in a dose of 200 mug, and with placebo in patients with airways obstruction. 2 Both salmefamol and salbutamol are potent bronchodilators with a signficantly superior action over placebo at all times up to 8 h after treatment. 3 The mean peak percentage increases in FEV produced by the three active preparations were similar. The decline from peak values was significantly slower with salmefamol than with salbutamol. Neither drug produced tachycardia.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 788738      PMCID: PMC1428820          DOI: 10.1111/j.1365-2125.1976.tb00582.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  A double-blind trial of salmefanol, a new bronchodilator.

Authors:  D Bainbridge; G J McHardy; M V Hoare; C H Dash
Journal:  Postgrad Med J       Date:  1975-09       Impact factor: 2.401

2.  An economical method of comparing inhaled bronchodilators in reversible diffuse airways obstruction. With special reference to a beta-2 stimulant--salmefamol.

Authors:  S Lal; C H Dash; M D Gribben
Journal:  Thorax       Date:  1974-05       Impact factor: 9.139

3.  The bronchodilator effect of a new adrenergic aerosol--Salmefamol.

Authors:  M C Kennedy; C H Dash
Journal:  Acta Allergol       Date:  1972-02

4.  New class of selective stimulants of beta-adrenergic receptors.

Authors:  D Hartley; D Jack; L H Lunts; A C Ritchie
Journal:  Nature       Date:  1968-08-24       Impact factor: 49.962

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.